The study examined the use of a novel bioresorbable scaffold (BRS) for treating coronary artery disease. Over 200 patients with single de novo coronary lesions were implanted with the BRS. At 1 year, the BRS demonstrated good safety and efficacy outcomes with low rates of scaffold thrombosis and target lesion failure. The BRS is a promising technology for temporarily propping open blocked arteries.